c-MYC-induced genomic instability

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 4, 2014, Pages

  Kuzyk, Alexandra ^a   Mai, Sabine ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BURKITT LYMPHOMA; CHROMOSOME ABERRATION; CHROMOSOME REPLICATION; DNA DAMAGE; DNA REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; KARYOTYPING; NONHUMAN; ONCOGENE C MYC;

EID: 84891807050     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014373     Document Type: Article

References (164)

1. Adams J. M, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. 1985. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318: 533-538.
2. Arvanitis D. A, Spandidos DA. 2008. Deregulation of the G1/ S phase transition in cancer and squamous intraepithelial lesions of the uterine cervix: A case control study. Oncol Rep 20: 751-760.
3. Barlow J. H, Faryabi RB, Callén E, Wong N, Malhowski A, Chen H. T, Gutierrez-Cruz G, Sun HW, McKinnon P, Wright G., et al. 2013. Identification of early replicating fragile sites that contribute to genome instability. Cell 152: 620-632.
4. Beckman R. A, Loeb LA. 2005. Genetic instability in cancer: Theory and experiment. Semin Cancer Biol 15: 423-435.
5. Benner S. E, Wahl GM, Von Hoff DD. 1991. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs 2: 11-25.
6. Bindra R. S, Glazer PM. 2007. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: Role of the Myc/Max network. Cancer Lett 252: 93-103.
7. Bister K., Duesberg PH. 1980. Genetic structure of avian acute leukemia viruses. Cold Spring Harb Symp Quant Biol 44: 801-822.
8. Bryant H. E, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E., Kyle S, Meuth M, Curtin NJ, Helleday T. 2005. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
9. Bucci B., Agnano ID, Amendola D, Igea D, Citti A, Raza GH, Miceli R., Paula De U, Marchese R, Albini S, et al. 2005. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res 11: 2756-2767.
10. Bunte T., Greiser-Wilke I, Moelling K. 1983. The transforming protein of the MC29-related virus CMII is a nuclear DNA-binding protein whereasMH2codes for a cytoplasmic RNA-DNA binding polyprotein. EMBO J 2: 1087-1092.
11. Campaner S., Amati B. 2012. Two sides of the Myc-induced DNA damage response: From tumor suppression to tumor maintenance. Cell Div 7: 6.
12. Caporali A., Wark L, Vermolen BJ, Garini Y, Mai S. 2007. Telomeric aggregates and end-to-end chromosomal fusions require myc box II. Oncogene 26: 1398-1406.
13. Casillas M. A, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO. 2003. Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 316: 57-65.
14. Chen Q., Shi X, Rudolph C, Yu Y, Zhang D, Zhao X, Mai S, Wang G., Schlegelberger B, Shi Q. 2011. Recurrent trisomy and Robertsonian translocation of chromosome 14 in murine iPS cell lines. Chromosome Res 19: 857-868.
15. Chernova O. B, Chernov MV, Ishizaka Y, Agarwal ML, Stark GR. 1998. MYC abrogates p53-mediated cell cycle arrest inN-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. Mol Cell Biol 18: 536-545.
16. Chiang Y.-C, Teng S-C, Su Y-N, Hsieh F-J, Wu K-J. 2003. c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair. J Biol Chem 278: 19286-19291.
17. Chiswell D. J, Ramsay G, Hayman MJ. 1981. Two virus-specific RNA species are present in cells transformed by defective leukemia virus OK10. J Virol 40: 301-304.
18. Chuang T. C, Moshir S, Garini Y, Chuang AY, Young IT, Vermolen B, van den Doel R, Mougey V, Perrin M, Braun M, et al. 2004. The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol 2: 12.
19. Cimprich K., Cortez D. 2008. ATR: An essential regulator of genome integrity. Nat Rev Mol Cell Biol 9: 616-627.
20. Classon M., Henriksson M, Sümegi J, Klein G, Hammarskjöld ML. 1987. Elevated c-myc expression facilitates the replication of SV40 DNA in human lymphoma cells. Nature 330: 272-274.
21. Classon M., Henriksson M, Klein G, Sümegi J. 1990. The effect of myc proteins on SV40 replication in human lymphoid cells. Oncogene 5: 1371-1376.
22. Cole K., Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, Diskin SJ, Attiyeh EF, Sennett R, Norris G, et al. 2011. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci 108: 3336-3341.
23. Conacci-Sorrell M, McFerrin L, Eisenman RN. 2014. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4: a014357.
24. Cooper G.M. 1982. Transforming genes of chicken bursal lymphomas. J Cell Physiol 1 (Suppl): 209-212.
25. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce C.M. 1982. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci 79: 7824-7827.
26. Dang C.V. 2012. Links between metabolism and cancer. Genes Dev 26: 877-890.
27. Dang C. V, Li F, Lee LA. 2005. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? Cell Cycle 4: 1465-1466.
28. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, et al. 2001. c-MYCinduces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235-239.
29. Denis N., Kitzis A, Kruh J, Dautry F, Corcos D. 1991. Stimulation of methotrexate resistance and dihydrofolate reductase gene amplification by c-myc. Oncogene 6: 1453-1457.
30. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R. 2007. Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451.
31. Donehower L. A, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
32. Duesberg P. H, Vogt PK. 1979. Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: Evidence for a second class of transforming genes. Proc Natl Acad Sci 76: 1633-1637.
33. Eberhardy S. R, Farnham PJ. 2001. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J Biol Chem 276: 48562-48571.
34. Eilers M., Picard D, Yamamoto KR, Bishop JM. 1989. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature 340: 66-68.
35. El Gedaily A, Bubendorf L, Willi N, FuW, Richter J, Moch H, Mihatsch M. J, Sauter G, Gasser TC. 2001. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 15: 184-190.
36. Ellerman V., Bang O. 1908. Experimentelle Leukämie bei Hühnern. Zentralbl Bakteriol Parasitenkd InfectionskrHyg Abt I 46: 595-609.
37. Felsher D. W, Bishop JM. 1999a. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207.
38. Felsher D. W, Bishop JM. 1999b. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci 96: 3940-3944.
39. Fernandez P. C, Frank SR, Wang L, Schroeder M, Liu S, Greene J., Cocito A, Amati B. 2003. Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
40. Ferrao P. T, Bukczynska EP, Johnstone RW, McArthur G. 2011. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 31: 1-12.
41. Fest T., Mougey V, Dalstein V, Hagerty M, Milette D, Silva S, Mai S. 2002. c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene 21: 2981-2990.
42. Fest T., Guffei A, Williams G, Silva S, Mai S. 2005. Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein. Oncogene 24: 2944-2953.
43. Fukasawa K. 2007. Oncogenes and tumour suppressors take on centrosomes. Nat Rev Cancer 7: 911-924.
44. Fukasawa K., Choi T, Kuriyama R, Rulong S, Vande Woude GF. 1996. Abnormal centrosome amplification in the absence of p53. Science 271: 1744-1747.
45. Fukasawa K., Wiener F, Vande Woude GF, Mai S. 1997. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15: 1295-1302.
46. Gabay M., Li Y, Felsher DW. 2014. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014241.
47. Gadji M., Vallente R, Klewes L, Righolt C, Wark L, Kongruttanachok N, Knecht H, Mai S. 2011. Nuclear remodeling as a mechanism for genomic instability in cancer. Adv Cancer Res 112: 77-126.
48. Gadji M., Adebayo Awe J, Rodrigues P, Kumar R, Houston DS, Klewes L, Die'ye TN, Rego EM, Passetto RF, et al. 2012. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin Cancer Res 18: 3293-3304.
49. Gallant P. 2013. MYC function in Drosophila. Cold Spring Harb Perspect Med 3: a014324.
50. Gandarillas A., Davies D, Blanchard JM. 2000. Normal and c-Myc-promoted human keratinocyte differentiation both occur via a novel cell cycle involving cellular growth and endoreplication. Oncogene 19: 3278-3289.
51. Gao P., Zhang H, Dinavahi R, Li F, Xiang Y, Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, et al. 2007. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12: 230-238.
52. Gaubatz J.W. 1990. Extrachromosomal circular DNAs and genomic sequence plasticity in eukaryotic cells. Mutat Res 237: 271-292.
53. George R. E, Kenyon RM, McGuckin AG, Malcolm AJ, Pearson AD, Lunec J. 1996. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group. Oncogene 12: 1583-1587.
54. Gonçalves Dos Santos Silva A, Sarkar R, Harizanova J, Guffei A, Mowat M, Garini Y, Mai S. 2008. Centromeres in cell division, evolution, nuclear organization and disease. J Cell Biochem 104: 2040-2058.
55. Gorrini C., Squatrito M, Luise C, Syed N, Perna D, Wark L, Martinato F., Sardella D, Verrecchia A, Bennett S, et al. 2007. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature 448: 1063-1067.
56. Grandori C., Cowlye SM, James LP, Eisenman RN. 2000. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699.
57. Grandori C., Wu K-J, Fernandez P, Ngouenet C, Grim J, Clurman B. E, Moser MJ, Oshima J, Russell DW, Swisshelm K, et al. 2003. Werner syndrome protein limits MYC-induced cellular senescence. Genes Dev 17: 1569-1574.
58. Graux C., Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R., Vermeesch JR, Stul M, Dutta B, Boeckx N, et al. 2004. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 36: 1084-1089.
59. Guffei A., Lichtensztejn Z, Gonçalves Dos Santos Silva A, Louis S. F, Caporali A, Mai S. 2007. c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. Neoplasia 9: 578-588.
60. Guijon F. B, Greulich-Bode K, Paraskevas M, Baker P, Mai S. 2007. Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: Possible biomarkers. J Low Genit Tract Dis 11: 265-272.
61. Hanahan D., Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
62. Hann S. R, Abrams HD, Rohrschneider LR, Eisenman RN. 1983. Proteins encoded by v-myc and c-myc oncogenes: Identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines. Cell 34: 789-798.
63. Hayward W. S, Neel BG, Astrin SM. 1981. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290: 475-480.
64. Henriksson M., Classon M, Hammarskjöld ML, Klein G, Sumegi J. 1988. The replication activity of SV40 DNA correlates with the level of c-myc expression in human tumor cell lines. Curr Top Microbiol Immunol 141: 202-207.
65. Hironaka K., Factor VM, Calvisi DF, Conner E, Thorgeirsson SS. 2003. Dysregulation of DNA repair pathways in a transforming growth factor a/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. Lab Invest 83: 643-654.
66. Höglund A., Nilsson LM, Muralidharan SV, Hasvold L, Merta P., Rudelius M, Nikolova V, Keller U, Nilsson J. 2011a. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells. Clin Cancer Res 17: 7067-7079.
67. Höglund A., Stromvall K, Li Y, Forshell LP, Nilsson JA. 2011b. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition. Cell Cycle 10: 3598-3607.
68. Hulf T., Bellosta P, Furrer M, Steiger D, Svensson D, Barbour A, Gallant P. 2005. Whole-genome analysis reveals a strong positional bias of conserved dMyc-dependent E-boxes. Mol Cell Biol 25: 3401-3410.
69. Huppi K., Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin S. E, Mushinski JF, Stephens R, Caplen NJ. 2008. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol Cancer Res 6: 212-221.
70. Huppi K., Pitt J, Wahlberg B, Caplen NJ. 2011. Genomic instability and mouse microRNAs. ToxicolMechMethods 21: 325-333.
71. Hurlin P.J. 2013. Control of vertebrate development by MYC. Cold Spring Harb Perspect Med 3: a014332.
72. Jain M., Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297: 102-104.
73. Kan N. C, Flordellis CS, Garon CF, Duesberg PH, Papas TS. 1983. Avian carcinoma virus MH2 contains a transformation-specific sequence, mht, and shares the myc sequence with MC29, CMII, and OK10 viruses. Proc Natl Acad Sci 80: 6566-6570.
74. Karlsson A., Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. 2003a. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci 100: 9974-9979.
75. Karlsson A., Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher D.W. 2003b. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 101: 2797-2803.
76. Khanna K. K, Jackson SP. 2001. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 27: 247-254.
77. Koch H. B, Zhang R, Verdoodt B, Bailey A, Zhang C-D, Yates JR 3rd, Menssen A, Hermeking H. 2007. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell Cycle 6: 205-217.
78. Kuschak T. I, Taylor C, McMillan-Ward E, Israels S, Henderson DW, Mushinski JF, Wright JA, Mai S. 1999. The ribonucleotide reductase R2 gene is a non-transcribed target of c-Myc-induced genomic instability. Gene 238: 351-365.
79. Kuschak T. I, Kuschak BC, Taylor CL, Wright JA, Wiener F, Mai S. 2002. c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene. Oncogene 21: 909-920.
80. Kuttler F., Mai S. 2007. Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis. Semin Cancer Biol 17: 56-64.
81. Lacoste S., Wiechec E, Dos Santos Silva AG, Guffei A, Williams G, Lowbeer M, Benedek K, Henriksson M, Klein G, Mai S. 2010. Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 29: 503-515.
82. Land H., Parada LF, Weinberg RA. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304: 596-602.
83. Land H., Chen AC, Morgenstern JP, Parada LF, Weinberg RA. 1986. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 6: 1917-1925.
84. LevensD. 2013. CellularMYCro economics: BalancingMYC function with MYC expression. Cold Spring Harb Perspect Med 3: a014233.
85. Li Q., Dang CV. 1999. c-Myc overexpression uncouplesDNA replication from mitosis. Mol Cell Biol 19: 5339-5351.
86. Li Z., Vam Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. 2003. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci 100: 8164-8169.
87. Li Z., Owonikoko T, Ramalingam SS, Doetsch PW, Xiao Z, Khuri F., Curran W, Deng X. 2012. c-Myc suppression of DNA double-strand break repair. Neoplasia 14: 1190-1202.
88. Lin C. Y, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee T. I, Young RA. 2012. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151: 56-67.
89. Liu Y.-C, Li F, Handler J, Huang CRL, Xiang Y, Neretti N, Sedivy J. M, Zeller KI, Dang CV. 2008. Global regulation of nucleotide biosynthetic genes by c-Myc. PloS ONE 3: e2722.
90. Liyanage M., Weaver Z, Barlow C, Coleman A, Pankratz DG, Anderson S., Wynshaw-Boris A, Ried T. 2000. Abnormal rearrangement within the a/d T-cell receptor locus in lymphomas from Atm-deficient mice. Blood 96: 1940-1946.
91. López-Contreras AJ, Fernandez-Capetillo O. 2010. The ATR barrier to replication-born DNA damage. DNA Repair 9: 1249-1255.
92. Louis S. F, Vermolen BJ, Garini Y, Young IT, Guffei A, Lichtensztejn Z, Kuttler F, Chuang TC, Moshir S, Mougey V, et al. 2005. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. Proc Natl Acad Sci 102: 9613-9618.
93. Lücke-Huhle C. 1994. Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. Carcinogenesis 15: 695-700.
94. Lücke-Huhle C, Mai S, Moll J. 1997. C-myc overexpression facilitates radiation-induced DHFR gene amplification. Int J Radiat Biol 71: 167-175.
95. Luoto K. R, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn L. Z, Bristow RG. 2010. Tumor cell kill by c-MYC depletion: Role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res 70: 8748-8759.
96. Maclean K. H, Kastan MB, Cleveland JL. 2007. Atm deficiency affects both apoptosis and proliferation to augment Myc-induced lymphomagenesis. Mol Cancer Res 5: 705-711.
97. Mai S. 1994. Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene 148: 253-260.
98. Mai S. 2010. Initiation of telomere-mediated chromosomal rearrangements in cancer. J Cell Biochem 109: 1095-1102.
99. Mai S., Garini Y. 2005. Oncogenic remodeling of the threedimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. Cell Cycle 4: 1327-1331.
100. Mai S., Garini Y. 2006. The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem 97: 904-915.
101. Mai S., Wiener F. 2002. The impact of p53 loss on murine plasmacytoma development. Chromosome Res 10: 239-251.
102. Mai S., Fluri M, Siwarski D, Huppi K. 1996a. Genomic instability in MycER-activated Rat1A-MycER cells. Chromosome Res 4: 365-371.
103. Mai S., Hanley-Hyde J, Fluri M. 1996b. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 12: 277-288.
104. Mai S., Hanley-Hyde J, Rainey GJ, Kuschak TI, Paul JT, Littlewood T. D, Mischak H, Stevens LM, Henderson DW, Mushinski JF. 1999. Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. Neoplasia 1: 241-252.
105. Mai S., Guffei A, Fest T, Mushinski JF. 2005. c-Myc deregulation promotes a complex network of genomic instability. In: Hormonal carcinogenesis IV (ed. Li JJ, Li SA, Llombart-Bosch A), pp. 87-97. Springer, New York.
106. Mannava S., Grachtchouk V, Wheeler LJ, Im M, Zhuang D, Slavina E. G, Mathews CK, Shewach DS, Nikiforov MA. 2008. Direct role of nucleotide metabolism in c-Mycdependent proliferation of melanoma cells. Cell Cycle 7: 2392-2400.
107. Manolov G., Manolova Y. 1972. Marker band in one chromosome 14 from Burkitt's lymphoma. Nature 237: 33-34.
108. McKeown MR, Bradner JE. 2014. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a014266.
109. Menssen A., Hermeking H. 2002. Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes. ProcNatl Acad Sci 99: 6274-6279.
110. Meyer N., Penn LZ. 2008. Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976-990.
111. Miltenberger R. J, Sukow KA, Farnham PJ. 1995. An E-boxmediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol Cell Biol 15: 2527-2535.
112. Moser R., Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J., Morgan M, Kemp CJ, Grandori C. 2012. MYCdriven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res 10: 535-545.
113. Murga M., Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montaña MF, D'Artista L, Schleker T, Guerra C, Garcia E., et al. 2011. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 18: 1331-1335.
114. Neel B. G, Hayward WS, Robinson HL, Fang J, Astrin SM. 1981. Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: Oncogenesis by promoter insertion. Cell 23: 323-334.
115. Neiman P., Wolf C, Enrietto PJ, Cooper G. 1985. A retroviral myc gene induces preneoplastic transformation of lymphocytes in a bursal transplantation assay. Proc Natl Acad Sci 82: 222-226.
116. Neiman P. E, Kimmel R, Icreverzi A, Elsaesser K, Bowers SJ, Burnside J., Delrow J. 2006. Genomic instability during Myc-induced lymphomagenesis in the bursa of Fabricius. Oncogene 25: 6325-6335.
117. Neiman P. E, Elsaesser K, Loring G, Kimmel R. 2008. Myc oncogene-induced genomic instability: DNA palindromes in bursal lymphomagenesis. PLoS Genet 4: e1000132.
118. Nesbit C. E, Tersak JM, Prochownik EV. 1999. MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
119. Nie Z., Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green D. R, Tessarollo L, Casellas R, et al. 2012. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68-79.
120. O'Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak M. K, Sedivy JA. 2003. A large scale genomic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278: 12563-12573.
121. Ohno S., Babonits M, Wiener F, Spira J, Klein G, Potter M. 1979. Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell 18: 1001-1007.
122. Orian A., van Steensel B, Delrow J, Bussemaker HJ, Li L, Sawado T., Williams E, Loo LW, Cowley SM, Yost C, et al. 2003. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev 17: 1101-1114.
123. Palmieri S., Kahn P, Graf T. 1983. Quail embryo fibroblasts transformed by four v-myc-containing virus isolates show enhanced proliferation but are non tumorigenic. EMBOJ 2: 2385-2389.
124. Payne G. S, Bishop JM, Varmus HE. 1982. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. Nature 295: 209-214.
125. Pear W. S, Ingvarsson S, Steffen D, Münke M, Francke U, Bazin H., Klein G, Sümegi J. 1986. Multiple chromosomal rearrangements in a spontaneously arising t(6;7) rat immunocytoma juxtapose c-myc and immunoglobulin heavy chain sequences. ProcNatlAcad Sci 83: 7376-7380.
126. Pierce S. B, Yost C, Britton JS, Loo LW, Flynn EM, Edgar BA, Eisenman R.N. 2004. dMyc is required for larval growth and endoreplication in Drosophila. Development 131: 2317-2327.
127. Potter M., Wiener F. 1992. Plasmacytomagenesis in mice: Model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 13: 1681-1697.
128. Prochownik E.V. 2008. c-Myc: Linking transformation and genomic instability. Curr Mol Med 8: 446-458.
129. Prochownik E. V, Li Y. 2007. The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 6: 1024-1029.
130. Pusapati R. V, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K., McArthur MJ, Wong PK, Johnson DG. 2006. ATM promotes apoptosis and suppresses tumorigenesis in response toMyc. ProcNatl Acad Sci 103: 1446-1451.
131. Ragimov N., Krauskopf A, Navot N, Rotter V, Oren M, Aloni Y. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8: 1183-1193.
132. Rahl P. B, Young RA. 2014. MYC and transcription elongation. Cold Spring Harb Perspect Med 4: a020990.
133. Ray S., Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg L, Felsher DW. 2006. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 66: 6598-6605.
134. Richards S. 2012. New type ofDNAdiscovered? The Scientist doi: 1-.1126/science.1213307.
135. Robinson K., Asawachaicharn N, Galloway D, Grandori C. 2009. c-Myc accelerates S-phase and requires WRN to avoid replication stress. PloS ONE 4: e5951.
136. Rockwood L. D, Torrey TA, Kim JS, Coleman AE, Kovalchuk AL, Xiang S, Ried T, MorseHCIII, Janz S. 2002. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene 21: 7235-7240.
137. Rounbehler R. J, LiW, Hall MA, Yang C, Fallahi M, Cleveland JL. 2009. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 69: 547-553.
138. Rous P. 1910. A transmissible avian neoplasm (sarcoma of the common fowl). J Exp Med 12: 696-705.
139. Rous P. 1911. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 13: 397-411.
140. Schoppy D. W, Ragland RL, Gilad O, Shastri N, Peters A, Murga M., Fernandez-Capetillo O, Diehl JA, Brown EJ. 2012. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 122: 241-252.
141. Scionti I., Michelacci F, Pasello M, Hattinger CM, Alberghini M, Manara MC, Bacci G, Ferrari S, Scotlandi K, Picci P, Serra M. 2008. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. Ann Oncol 19: 1500-1508.
142. Shen-Ong GL, Keath EJ, Piccoli SP, Cole MD. 1982. Novel myc oncogene RNA from abortive immunoglobulingene recombination in mouse plasmacytomas. Cell 31: 443-452.
143. Shibata Y., Kumar P, Layer R, Willcox S, Gagan JR, Griffith JD, Dutta A. 2012. Extrachromosomal microDNAs and chromosomal microdeletions in normal tissues. Science 336: 82-86.
144. Shreeram S., Hee WK, Demidov ON, Kek C, Yamaguchi H, Fornace A. J, Anderson CW, Appella E, Bulavin DV. 2006. Regulation of ATM/p53-dependent suppression of mycinduced lymphomas by Wip1 phosphatase. J Exp Med 203: 2793-2799.
145. Sidorova J. M, Li N, Folch A, Monnat RJ Jr. 2008. The RecQ helicase WRN is required for normal replication fork progression after DNA damage or replication fork arrest. Cell Cycle 7: 796-807.
146. Silva A. G, Graves HA, Guffei A, Ricca TI, Mortara RA, Jasiulionis M. G, Mai S. 2010. Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia 12: 11-19.
147. Smith G., Taylor-Kashton C, Dushnicky L, Symons S, Wright J, Mai S. 2003. c-Myc-induced extrachromosomal elements carry active chromatin. Neoplasia 5: 110-120.
148. Solovei I., Kreysing M, Lanctot C, Kösem S, Peichl L, Cremer T, Guck J, Joffe B. 2009. Nuclear architecture of rod photoreceptor cells adapts to vision inmammalian evolution. Cell 137: 356-368.
149. Stehelin D., Varmus HE, Bishop JM, Vogt PK. 1976. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170-173.
150. Sun Y., Jiang X, Chen S, Fernandes N, Price BD. 2005. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc Natl Acad Sci 102: 3182-3187.
151. Swarnalatha M., Singh AK, Kumar V. 2012. The epigenetic control of E-box and Myc-dependent chromatin modifications regulate the licensing of lamin B2 origin during cell cycle. Nucleic Acids Res 40: 9021-9035.
152. Tanaka H., Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y. 2002. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9: 1017-1029.
153. Taub R., Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S., Leder P. 1982. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci 79: 7837-7841.
154. Taylor C., Mai S. 1998. c-Myc-associated genomic instability of the dihydrofolate reductase locus in vivo. Cancer Detect Prev 22: 350-356.
155. Thompson C. B, Humphries EH, Carlson LM, Chen CL, Neiman PE. 1987. The effect of alterations in myc gene expression on B cell development in the bursa of Fabricius. Cell 51: 371-381.
156. Vafa O., Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, Wahl GM. 2002. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol Cell 9: 1031-1044.
157. Vermolen B. J, Garini Y, Mai S, Mougey V, Fest T, Chuang TC, Chuang A. Y, Wark L, Young IT. 2005. Characterizing the three-dimensional organization of telomeres. Cytometry A 67: 144-150.
158. Weaver B. A, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. 2006. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11: 25-36.
159. Weinstein I.B. 2002. Cancer. Addiction to oncogenes-The Achilles heal of cancer. Science 297: 63-64.
160. Wiener F., Kuschak TI, Ohno S, Mai S. 1999. Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes. Proc Natl Acad Sci 96: 13967-13972.
161. Windle B., Draper BW, Yin YX, O'Gorman S, Wahl GM. 1991. A central role for chromosome breakage in gene amplification, deletion formation, and amplicon integration. Genes Dev 5: 160-174.
162. Wonsey D. R, Zeller KI, Dang CV. 2002. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. PNAS 99: 6649-6654.
163. Zasadil L. M, Britigan EM, Weaver BA. 2013. 2n or not 2n: Aneuploidy, polyploidy and chromosomal instability in primary and tumor cells. Semin Cell Dev Biol 24: 370-379.
164. Zech L., Haglund U, Nilsson K, Klein G. 1976. Characteristic chromosomal abnormalities in biopsies and lymphoidcell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 17: 47-56.